arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

AN2 Therapeutics, Inc.

ANTX

$4.83 ▼ -0.01 (-0.31%) at close

6 Visible periods

17 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

AN2 Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $145.9M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -56.7% ↘

FCF / Share $-0.99 ↗

Trailing P/E —

Price / Book 2.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-35.17M

↑ +31.5% —

FCF / Share Free cash flow per share

$-0.99

↑ +40.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
EPS Growth YoY (%)	32.6% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	37.2% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	1.8% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	73.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	31.5% Excellent ↑ Excellent Improving Year-over-year change in net income	20.7% Good ↑ Good Improving Year-over-year change in net income	-58.1% Weak Weak Year-over-year change in net income	-90.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	40.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	26.9% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	-3.5% Weak Weak Year-over-year change in free cash flow	71.9% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
FCF / Net Income (x)	0.85x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-56.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-54.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-44.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-35.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	35.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-61.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-61.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-50.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-41.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-33.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-66.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-542%)	-62.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-518%)	-51.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-446%)	-42.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-386%)	45.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+203%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Net Debt (USD)	$-19.94M	$-21.35M	$-15.65M	$-27.22M	$-12.10M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Basic EPS, GAAP (USD)	$-1.16	$-1.72	$-2.74	$-2.79	$-10.64	—
Free Cash Flow per Share (USD)	$-0.99	$-1.65	$-2.26	$-2.18	$-7.76	—
Book Value per Share (USD)	$1.94	$2.74	$4.19	$4.92	$-17.36	—
Tangible Book Value per Share (USD)	$1.94	$2.74	$4.19	$4.92	$-17.36	—
Basic Weighted Avg Shares (shares)	30.22M	29.83M	23.60M	15.34M	2.64M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$51.22M	$76.02M	$96.46M	$91.44M	$56.71M	—
Total Equity (USD)	$53.06M	$81.85M	$124.70M	$95.37M	$-47.41M	$-20.32M

📋 What is driving earnings? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Net Income, GAAP (USD)	$-35.17M	$-51.32M	$-64.73M	$-40.96M	$-21.54M	—
Operating Cash Flow (USD)	$-29.83M	$-49.26M	$-53.29M	$-33.46M	$-20.48M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 23 quarters

AN2 Therapeutics, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ANTX with peers